Sarepta Therapeutics shares rise 2.96% intraday as investors anticipate key economic data and potential Fed rate cuts.

Sarepta Therapeutics, Inc. rose 2.96% intraday. The stock's movement aligns with the broader market sentiment as investors anticipate key economic data releases, including consumer price figures and producer price index data, which could influence the Federal Reserve's interest rate decisions. Additionally, the stock's performance may be influenced by the overall market's reaction to trade policy developments, particularly the impact on major chip companies.